Breast Cancer Clinical Trial
GeneSearchâ„¢ Breast Lymph Node (BLN) Assay Post Approval Study
Summary
This post-approval study is designed to determine the performance of the FDA-approved GeneSearchâ„¢ BLN Assay when compared to the site's standard of care permanent section histological evaluation, and when compared to more extensive histological evaluation when the assay is being used by clinicians to make surgical decisions on complete axillary dissections (ALND).
Full Description
The primary objective of this clinical study is to gather data to estimate the positive predictive concordance (PPC) between the GeneSearchâ„¢ BLN Assay and histology as routinely practiced, i.e., routine H&E histology of sentinel lymph node(s) (SLN) and, when available, routine histology of non-sentinel axillary lymph nodes (ALN). This study will provide information on the assay that will augment the performance data gained in pre-market validation studies. In addition, with the assay being used for ALND decision-making, the metastatic status of the non-sentinel axillary nodes can be taken into account in the performance measures, i.e., if the patient's sentinel or non-sentinel nodes are histologically positive, the patient will be considered positive for the primary comparison to the assay results.
Eligibility Criteria
Inclusion Criteria:
Pre-operatively established diagnosis of invasive carcinoma of the breast
Scheduled for axillary sentinel lymph node dissection as per standard of care at the clinical site for newly diagnosed breast cancer patients
Patients for whom the GeneSearchâ„¢ BLN Assay will be used intra-operatively to make a decision for an axillary lymph node dissection
18 years of age or older
Female or male
Willing and able to give informed consent to participate in the study
Exclusion Criteria:
Previous diagnosis of lymphoma
Subjects participating in other research studies that would interfere with their full participation in this study
Patients and/or conditions with 'interfering substances' as listed in the IFU.
Patients who have had any pre-operative treatment for breast cancer including neoadjuvant and/or hormonal intervention such as aromatase inhibitors or tamoxifen
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 6 Locations for this study
Los Angeles California, 90048, United States
Washington District of Columbia, 20007, United States
Clearwater Florida, 33756, United States
St. Petersburg Florida, 33705, United States
Augusta Georgia, 30912, United States
Flowood Mississippi, 39232, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.